SavedAdd your journal

Journals / İstanbul Kuzey Klinikleri / 2018 / Cilt: 5 - Sayı: 4

The effects of short-term use of granulocyte colony-stimulating factor on bone metabolism in child cancer patients

Ayşe BOZKURT TURHAN
Enver ŞİMŞEK
Ciğdem BİNAY
Özcan BOR
Pages
277–281
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the control group, the measurements were made during corticosteroid andmethotrexate-free chemotherapy.RESULTS: The mean osteocalcin level (8.6±2.3 ng/mL) from before the onset of treatment decreased significantly (7.7±2.3ng/mL) on day 3 of G-CSF therapy and significantly increased after 7 days of G-CSF therapy (7.9±2.2 ng/mL) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The granulocyte colony-stimulating factor (G-CSF) is the most commonly used hematopoietic growth factorrecombinant DNA technology.
📊
Key Findings & Data:The aimof the present study was to investigate the effects of short-term use of G-CSF on bone metabolism in children with leukemiaand solid tumors.METHODS: Thirty-six patients with a malignancy who received G-CSF therapy according to chemotherapy protocols and another20 growth factor-free cancer patients who were enrolled as controls were included in the study.
💡
Conclusion & Impact:In the control group, the measurements were made during corticosteroid andmethotrexate-free chemotherapy.RESULTS: The mean osteocalcin level (8.6±2.3 ng/mL) from before the onset of treatment decreased significantly (7.7±2.3ng/mL) on day 3 of G-CSF therapy and significantly increased after 7 days of G-CSF therapy (7.9±2.2 ng/mL) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The granulocyte colony-stimulating factor (G-CSF) is the most commonly used hematopoietic growth factorrecombinant DNA technology. It affects bone metabolism by modulating both osteoclast and osteoblast functions. The aimof the present study was to investigate the effects of short-term use of G-CSF on bone metabolism in children with leukemiaand solid tumors.METHODS: Thirty-six patients with a malignancy who received G-CSF therapy according to chemotherapy protocols and another20 growth factor-free cancer patients who were enrolled as controls were included in the study. The serum osteocalcinand urinary free deoxypyridinoline levels were measured before the start of G-CSF therapy, on day 3 after treatment, and 7days after G-CSF therapy was discontinued. In the control group, the measurements were made during corticosteroid andmethotrexate-free chemotherapy.RESULTS: The mean osteocalcin level (8.6±2.3 ng/mL) from before the onset of treatment decreased significantly (7.7±2.3ng/mL) on day 3 of G-CSF therapy and significantly increased after 7 days of G-CSF therapy (7.9±2.2 ng/mL) (p

🔖

Cite This Article

TURHAN, A. B., ŞİMŞEK, E., BİNAY, C., BOR, Ö. (2022). The effects of short-term use of granulocyte colony-stimulating factor on bone metabolism in child cancer patients. İstanbul Kuzey Klinikleri, Cilt: 5 - Sayı: 4, 277–281. https://ajindex.com/articles/652041

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002;116:28–56
  2. Froberg MK, Garg UC, Stroncek DF, Geis M, McCullough J, Brown DM. Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocytecolony- stimulating factor for peripheral blood stem and progenitor cell collection. Transfusion 1999;39:410–4
  3. Steward WP. Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet 1993;342:153–7
  4. Kuwabara H, Wada T, Oda T, Yoshikawa H, Sawada N, Kokai Y, et al. Overexpression of the granulocyte colony-stimulating factor gene impairs bone morphogenetic protein responsiveness in mice. Lab Invest 2001;81:1133–41
  5. Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997;30:573–93
  6. Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 1993;3:255–60
  7. Husain SM, Mughal Z, Williams G, Ward K, Smith CS, Dutton J, et al. Urinary excretion of pyridinium crosslinks in healthy 4-10 year olds. Arch Dis Child 1999;80:370–3
  8. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med 1993;25:385–93
  9. Romberg RW, Werness PG, Riggs BL, Mann KG. Inhibition of hydroxyapatite crystal growth by bone-specific and other calcium-binding proteins. Biochemistry 1986;25:1176–80
  10. Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003;72:82–93
  11. Lee MY, Fukunaga R, Lee TJ, Lottsfeldt JL, Nagata S. Bone modulation in sustained hematopoietic stimulation in mice. Blood 1991;77:2135–41
  12. Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Lévesque JP. Osteoclast-mediated bone resorption is stimulated during short- -term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 1998;92:3465–73
  13. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006;124:407–21
  14. Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I, et al. G-CSF potently inhibits osteoblast activity and